Expression of Bcl-2 and Ki-67 in tamoxifen-associated endometrial polyps: Comparison with postmenopausal polyps

Onkologie

Volumn 29, Issue 8-9, 2006, Pages 376-380

  Altaner, Semsi ^a   Gucer, Fatih ^b   Tokatli, Fusun ^a   Guresci, Servet ^a   Ozdemir, Cigdem ^a   Puyan, Fulya Oz ^a   Kutlu, Kemal ^a  

^a TRAKYA UNIVERSITY   (Turkey)

^b Anadolu Saglik Merkezi ^*  (Turkey)

Author keywords

Bcl 2; Ki 67; Polyps: endometrial, postmenopausal; Tamoxifen

Indexed keywords

HEMATOXYLIN; KI 67 ANTIGEN; PARAFFIN; PROTEIN BCL 2; TAMOXIFEN;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POSTMENOPAUSE; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

ENDOMETRIUM; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; POLYPS; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TAMOXIFEN; UTERINE DISEASES;

EID: 33748571184     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094443     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group: Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
2. Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I: Recurrent endometrial polyps in PM breast cancer patients on tamoxifen. Gynecol Oncol 2003;90:382-6.
3. Cohen I, Azaria R, Aviram R, Bernheim J, Tepper R, Cordoba M, Beyth Y: PM Endometrial pathologies with tamoxifen treatment: comparison between hysteroscopic and hysterectomy findings. Gynecol Obstet Invest 1999;48:187-92.
4. Cohen I, Bernheim J, Azaria R, Tepper R, Sharony R, Beyth Y: Malignant endometrial polyps in PM breast cancer tamoxifen-treated patients. Gynecol Oncol 1999;75:136-41.
5. Houghton JP, Ioffe OB, Silverberg SG, McGrady B, McCluggage WG: Metastatic breast lobular carcinoma involving tamoxifen-associated endometrial polyps: report of two cases and review of tamoxifen-associated polypoid uterine lesions. Mod Pathol 2003;16(4):395-8.
6. Sakuragi N, Salah-eldin AE, Watari H, Itoh T, Inoue S, Moriuchi T, Fujimato S: Bax, Bcl-2 and p53 expression in endometrial cancer. Gynecol Oncol 2002;86:288-96.
7. Schlesinger C, Silverberg SG: Tamoxifen-associated polyps (basalomas) arising in multiple endometriotic foci: a case report and review of the literature. Gynecol Oncol 1999;73:305-11.
8. Timmerman D, Deprest J, Verbesselt R, Moerman P, De Branbanter J, Vergote I: Absence of correlation between risk factors for endometrial cancer and the presence of tamoxifen-associated endometrial polyps in PM patients with breast cancer. Eur J Cancer 2000;36:39-46.
9. Wilder JL, Shajahan S, Khattar NH, Wilder SM, Yin J, Rushing RS, Beaven R, Kaetzel C, Ueland FR, Van Nagell JR, Kryscio RJ, Lele SM: Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-α, estrogen-β and progesterone: a case controlled study. Gynecol Oncol 2004;92:553-8.
10. Cohen I: Endometrial pathologies associated with PM tamoxifen treatment. Gynecol Oncol 2004;94(2)256-66.
11. Gompel A, Sabourin JC, Martin A, Yaneva H, Audouin J, Decroix Y, Poitout P: Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994;144(6):1195-202.
12. Taylor LJ, Jackson TL, Reid JG, Duffy RG: The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki-67 in endometrial polyps. BJOG 2003;110(9):794-8.
13. Amezcua CA, Zheng W, Muderspach L, Felix JC: Down-regulation of Bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia. Gynecol Oncol 1999;73:126-36.
14. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Obermair A, Kimberger O, Czerwenka K: Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gynecol Oncol 2004;92:175-9.
15. Cohen I, Azaria R, Shapira J, Dror Y, Tepper R: The significance of secondary ultrasonographic endometrial thickening in PM tamoxifen-treated women. Cancer 2002;94:3101-106.
16. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B: Endometrial polyps in PM patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125-31.
17. Ramondetta LM, Sherwood JB, Dunton JD, Palazzo JP: Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol 1999;180:340-41.
18. Berliere M, Charles A, Galant C, Donnez J: Uterine side effects of tamoxifen: a need for systemic pretreatment screening. Obstet Gynecol 1998;91:40-4.
19. Deligdisch L, Kalir N, Cohen CJ, De Latour M, Le Bouedec G, Penault-Llorca F: Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000;78:181-6.
20. Cohen I, Altaras MM, Shapira J, Tepper R, Cordoba M, Figer A, Zalel Y, Dror Y, Beyth Y: Time-dependent effect of tamoxifen therapy on endometrial pathologies in asymptomatic, PM breast cancer patients. Int J Gynecol Pathol 1996;15:152-7.
21. Cohen I, Azaria R, Berheim J, Tepper R, Sharony R, Beyth Y: Risk factors of endometrial polyps resected from PM patients with breast carcinoma treated with tamoxifen. Cancer 2001;92:1151-55.
22. Ioffe OB, Papadimitriou JC, Drachenberg CB: Correlation of proliferation indices, apoptosis and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic and malignant endometrium. Hum Pathol 1998;29:1150-9.
23. Arends MJ: Apoptosis in the endometrium. Histopathology 1999;35:174-78.
24. Catasus L, Matias-Guiu X, Machin P, Munoz J, Prat J: BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrial carcinomas with microsatellite instability. Lab Invest 1998;78:1439-44.
25. Risberg B, Karlsson K, Abeler V, Lagrelius A, Davidson B, Karlsson MG: Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications. Int J Gynecol Pathol 2002;21(2):155-60.
26. Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY, Greaves MF: Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 1992;40:1819-25.
27. Niemann TH, Trogovac TL, McGaughy VR, Vaccarello L: Bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 1996; 63:318-22.
28. Vinatier D, Dufour P, Subtil D: Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Eur J Obstet Gynecol Reprod Biol 1996;67:85-102.
29. Otsuki Y, Misaki O, Sugimoto O, Ito Y, Tsujimoto Y, Akao Y. Cyclic bcl-2 expression in human uterine endometrium during menstrual cycle. Lancet 1994;344:28-9.
30. Zheng W, Feng Y, Gandhi M, Siu S, Hom E, Caputo T, Lauchlan SC: Persistent expression of bcl-2 onco-protein in endometrial carcinoma correlates with hormone receptor positivity. Int J Gynecol Cancer 1996;6:235-40.